Home › Products › Oncology › Idarubitec 5mg Injection
Idarubitec 5mg Injection
Salt Composition: IDARUBICIN
- Manufacturer: UNITED BIOTECH PVT LTD
- Pack Size: 1 VIAL(s)
- Dosage Form: INJECTION
- Strength: 5MG
- Prescription Required
- Storage: Store under refrigeration 2º to 8ºC Protect the medicine from light and keep the injection away from the reach of children and pets. If you have missed any dosing appointments, inform your doctor and schedule immediately.
₹6638.00₹8850.00
Inclusive of all taxes
Product Introduction
Idarubitec 5mg Injection contains idarubicin hydrochloride as the active substance. It is an antineoplastic drug belonging to the anthracycline class of medications. It is used in adults and children to treat acute non-lymphoblastic leukemia (ANLL), also known as acute myeloid leukemia (AML). It is also used in adults and children as a second-line treatment for relapsed acute lymphoblastic leukemia (ALL). It works by slowing or stopping the growth of cancer cells in the body.
Do not take Idarubitec 5mg Injection if you are allergic to idarubicin or any other ingredients in this medicine. Inform your physician if you have an infection, liver disease, kidney disease, heart disorder, stomach problems, or are breastfeeding. If your doctor has informed you that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.
Idarubitec 5mg Injection should not be used in pregnant and breastfeeding women. Inform your physician if you are pregnant or breastfeeding. Use effective contraception throughout therapy to avoid pregnancy. This medicine may affect male fertility. Discuss with your doctor if you are planning for pregnancy.
The common side effects are diarrhoea, nausea, vomiting, stomach cramps, and hair loss.
Uses
Acute myeloid leukemia (AML) Relapsed acute lymphoblastic leukemia (ALL)
How it works
Idarubitec 5mg Injection has antimitotic and cytotoxic effects via a variety of modes of action. It intercalates with DNA to form complexes, and it inhibits topoisomerase II activity by stabilising the DNA-topoisomerase II complex, blocking the relegation component of the ligation-religation reaction catalysed by topoisomerase II. It interferes with the ways in which the cells of your body grow and increase in number and is used in the treatment of cancers.
How to Use
It will be given to you by a doctor or nurse in a hospital or clinic setting who is trained in cancer chemotherapy. It is given as an intravenous infusion drip (into your vein). Do not self-administer the injection. Your doctor will decide the dose and duration of the treatment based on your disease severity, body weight, and other factors.
Side Effects
Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them. Common Hair loss Itchy skin rash Diarrhea Nausea, vomiting Stomach cramps Headache Serious Abnormal rhythm Chest pain Congestive heart failure Decreased bone marrow function Liver toxicity Kidney toxicity Infections
Expert Tips
Male patients with a female partner of reproductive potential are to use effective contraception during the therapy and for 3.5 months after the last dose. Immediately report symptoms of infection, anemia, or bleeding to your doctor. Do not breastfeed during the treatment and for 14 days after the previous dose. This medicine may cause infertility in both men and women; inform your doctor if you are planning for pregnancy before initiating the treatment. This medicine may make you bleed, bruise, or get infections more easily. Take precautions to prevent illness and injury. Wash your hands often. Your doctor may advise you to take certain tests to check for the effectiveness of the therapy.
References
- Zavedos 5mg Powder for Solution for Injection - Summary of Product Characteristics (SmPC) - (emc). www.medicines.org.uk. [revised 2022] [cited 2023 Apr 21]. Available from: https://www.medicines.org.uk/emc/product/5596/smpc
- Idamycin - Idarubicin hydrochloride [cited 2023 Apr 21]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/050734s027lbl.pdf
- Cersosimo RJ. Idarubicin: an anthracycline antineoplastic agent. Clinical Pharmacy. [revised 1992 Feb 1] [cited 2023 Apr 21];11(2):152â67. Available from: https://pubmed.ncbi.nlm.nih.gov/1551297/
Safety Advice
Pregnancy: unsafe Idarubitec 5mg Injection is unsafe to administer in pregnant women because it may affect the fetus. Inform your physician if you are pregnant, suspect pregnant, or planning to become pregnant. Using an effective birth control method during the treatment and for 6.5 months after your last dose is necessary.
Lungs: Consult your doctor It is unknown whether Idarubitec 5mg Injection can be used in patients with lung disorders. Consult your doctor if you have any lung diseases before starting the treatment.
Breastfeeding: unsafe Breastfeeding is not recommended in patients taking Idarubitec 5mg Injection because the medicine passes into the breast milk in small amounts and may harm your baby.
Disclaimer
The information provided on this page is intended for general informational purposes only and should not be considered as medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication. Self-medication can be harmful. Med For Rare does not endorse self-diagnosis or self-treatment.